Bicycle Therapeutics (NASDAQ:BCYC) CEO Sells 5,905 Shares of Stock

Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) CEO Kevin Lee sold 5,905 shares of the firm’s stock in a transaction dated Thursday, July 2nd. The stock was sold at an average price of $4.27, for a total value of $25,214.35. Following the completion of the sale, the chief executive officer directly owned 605,408 shares of the company’s stock, valued at approximately $2,585,092.16. This represents a 0.97% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Kevin Lee also recently made the following trade(s):

• On Monday, July 6th, Kevin Lee sold 1,737 shares of Bicycle Therapeutics stock. The stock was sold at an average price of $4.31, for a total value of $7,486.47.

Bicycle Therapeutics Stock Up 0.7%

Shares of BCYC traded up $0.03 during mid-day trading on Tuesday, hitting $4.38. 506,264 shares of the company traded hands, compared to its average volume of 439,849. Bicycle Therapeutics PLC Sponsored ADR has a 1-year low of $3.92 and a 1-year high of $9.18. The company has a market capitalization of $305.77 million, a PE ratio of -1.39 and a beta of 1.55. The business has a 50 day moving average of $4.40 and a 200 day moving average of $5.27.

Bicycle Therapeutics (NASDAQ:BCYC) last released its earnings results on Thursday, April 30th. The company reported ($0.87) EPS for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.25). The company had revenue of $0.89 million during the quarter, compared to analyst estimates of $7.50 million. Bicycle Therapeutics had a negative return on equity of 35.74% and a negative net margin of 344.95%. As a group, research analysts expect that Bicycle Therapeutics PLC Sponsored ADR will post -1.97 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on BCYC. Needham & Company LLC dropped their price objective on shares of Bicycle Therapeutics from $24.00 to $15.00 and set a “buy” rating on the stock in a report on Wednesday, March 18th. Morgan Stanley lowered their price target on Bicycle Therapeutics from $13.00 to $12.00 and set an “equal weight” rating for the company in a research report on Wednesday, April 8th. Royal Bank Of Canada dropped their price target on Bicycle Therapeutics from $11.00 to $7.00 and set a “sector perform” rating on the stock in a research note on Wednesday, March 18th. Oppenheimer cut their price objective on Bicycle Therapeutics from $44.00 to $36.00 and set an “outperform” rating on the stock in a report on Wednesday, March 18th. Finally, Truist Financial set a $8.00 price objective on Bicycle Therapeutics in a research note on Tuesday, March 17th. Five investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $14.00.

Institutional Trading of Bicycle Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. GSK plc purchased a new position in shares of Bicycle Therapeutics during the fourth quarter worth $10,829,000. Schroder Investment Management Group purchased a new stake in Bicycle Therapeutics in the fourth quarter valued at $3,976,000. Renaissance Technologies LLC boosted its holdings in Bicycle Therapeutics by 72.8% in the first quarter. Renaissance Technologies LLC now owns 979,300 shares of the company’s stock valued at $4,544,000 after purchasing an additional 412,700 shares during the last quarter. Woodline Partners LP acquired a new stake in Bicycle Therapeutics during the 1st quarter worth about $3,088,000. Finally, Birchview Capital LP grew its position in Bicycle Therapeutics by 200.5% during the 4th quarter. Birchview Capital LP now owns 462,700 shares of the company’s stock worth $3,276,000 after purchasing an additional 308,700 shares during the period. Institutional investors and hedge funds own 86.15% of the company’s stock.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc is a clinical-stage biotechnology company specializing in the discovery and development of novel peptide therapeutics based on its proprietary bicyclic peptide platform. The company’s core technology leverages constrained peptide structures that combine the binding specificity of biologics with the favorable tissue-penetration properties of small molecules. This approach is designed to generate highly selective drug candidates with potential applications across a range of therapeutic areas, including oncology, neuroscience and immunology.

Bicycle Therapeutics maintains a diversified pipeline of internally developed programs as well as collaborations with leading pharmaceutical partners.